Caris Life Sciences,�Inc. (CAI)
(Real Time Quote from BATS)
$28.50 USD
-1.80 (-5.94%)
Updated Aug 6, 2025 12:50 PM ET
3-Hold of 5 3
D Value D Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CAI 28.50 -1.80(-5.94%)
Will CAI be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CAI based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for CAI
Caris Life Sciences Publishes Study Showing AI Signature-positive Breast Cancer Patients Live ...
Caris Life Sciences publishes new study on AI-based image analysis model
Caris Life Sciences Inc (CAI) Unveils Breakthrough AI Tool for Cancer Diagnosis | CAI stock news
Caris Life Sciences Publishes Study Showing its Multi-Layer AI-Based Tissue of Origin ...
ClearBridge Select Strategy Q2 2025 Commentary